493 results on '"Urban, Stephan"'
Search Results
2. Structure of antiviral drug bulevirtide bound to hepatitis B and D virus receptor protein NTCP
3. Joint host-pathogen genomic analysis identifies hepatitis B virus mutations associated with human NTCP and HLA class I variation
4. Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies
5. Molecular determinants within the C-termini of L-HDAg that regulate hepatitis D virus replication and assembly
6. Broad-spectrum activity of bulevirtide against clinical isolates of HDV and recombinant pan-genotypic combinations of HBV/HDV
7. Potent broadly neutralizing antibody VIR-3434 controls hepatitis B and D virus infection and reduces HBsAg in humanized mice
8. Hepatitis D virus infection: Pathophysiology, epidemiology and treatment. Report from the first international delta cure meeting 2022
9. No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks treatment in phase II and III clinical trials for chronic hepatitis delta
10. Krise. Macht. Arbeit.: Über Krisen des Kapitalismus und Pfade in eine nachhaltige Gesellschaft
11. Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial
12. Effect of variants in LGP2 on MDA5-mediated activation of interferon response and suppression of hepatitis D virus replication
13. Dual role of neddylation in transcription of hepatitis B virus RNAs from cccDNA and production of viral surface antigen
14. Hepatitis D virus-induced interferon response and administered interferons control cell division-mediated virus spread
15. Mitosis of hepatitis B virus-infected cells in vitro results in uninfected daughter cells
16. Bulevirtide als erster spezifischer Wirkstoff gegen Hepatitis-D-Virusinfektionen – Mechanismus und klinische Wirkung
17. OS-122 Bulevirtide in combination with pegylated interferon alfa-2a shows a sustained off-treatment response in the liver
18. Analysis of Replication, Cell Division-Mediated Spread, and HBV Envelope Protein-Dependent Pseudotyping of Three Mammalian Delta-like Agents
19. De novo synthesis of hepatitis B virus nucleocapsids is dispensable for the maintenance and transcriptional regulation of cccDNA
20. Structure of hepatitis B/D antiviral drug Bulevirtide bound to its receptor protein NTCP
21. Author Reply to Peer Reviews of An HBV/HDV Infection Model Using Human Pluripotent Stem Cell-Derived Hepatocyte-Like Cells for Virus Host Interactions and Antiviral Evaluation
22. Concentration of Na+-taurocholate-cotransporting polypeptide expressed after in vitro-transcribed mRNA transfection determines susceptibility of hepatoma cells for hepatitis B virus
23. Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy
24. Development of a single‐domain antibody to target a G‐quadruplex located on the hepatitis B virus covalently closed circular DNA genome.
25. CARs derived from broadly neutralizing, human monoclonal antibodies identified by single B cell sorting target hepatitis B virus-positive cells.
26. Hepatitis D infection induces IFN-β-mediated NK cell activation and TRAIL-dependent cytotoxicity
27. Molecular determinants within the C-termini of L-HDAg that regulate hepatitis D virus replication and assembly
28. RBM39 shapes innate immunity through transcriptional and splicing control of IRF3 and other key factors
29. Human pluripotent stem cell-derived hepatocyte-like cells for hepatitis D virus studies
30. Hepatitis D virus replication is sensed by MDA5 and induces IFN-β/λ responses in hepatocytes
31. HBV Bypasses the Innate Immune Response and Does Not Protect HCV From Antiviral Activity of Interferon
32. T cell receptor grafting allows virological control of hepatitis B virus infection
33. Hepatitis D virus infection: Pathophysiology, epidemiology and treatment. Report from the first international delta cure meeting 2022
34. Infection of a Human Hepatoma Cell Line by Hepatitis B Virus
35. Stem cell-derived polarized hepatocytes
36. Analyse chromosomal integrierter HBV-DNA durch inverse nested PCR
37. CDK8 and CDK19: positive regulators of signal-induced transcription and negative regulators of Mediator complex proteins
38. An RNA-based system to study hepatitis B virus replication and evaluate antivirals
39. Evaluation of the drug-drug interaction potential of the novel hepatitis B and D virus entry inhibitor bulevirtide at OATP1B in healthy volunteers
40. In vitro cell culture models to study hepatitis B and D virus infection
41. Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections.
42. Entry of hepatitis B and hepatitis D virus into hepatocytes: Basic insights and clinical implications
43. Evidence that hepatitis B virus replication in mouse cells is limited by the lack of a host cell dependency factor
44. Generation and characterization of a stable cell line persistently replicating and secreting the human hepatitis delta virus
45. Recapitulation of HDV infection in a fully permissive hepatoma cell line allows efficient drug evaluation
46. Hepatitis D infection induces IFN-b-mediated NK cell activation and TRAILdependent cytotoxicity.
47. Hepatitis delta: Epidemiology to recent advances in therapeutic agents.
48. Hepatitis delta: epidemiology to recent advances in therapeutic agents
49. Quantification of the hepatitis B virus cccDNA: evidence-based guidelines for monitoring the key obstacle of HBV cure
50. Strong decline of intrahepatic HDV markers and signs of liver inflammation after 48 weeks of treatment with Bulevirtide in chronic hepatitis D patients: Combined intrahepatic results from the clinical trials MYR203 and MYR301
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.